Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Laekna Limited
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
98Moderate confidence
Mechanism Precedent
98High confidence
- Mechanism class: kinase inhibitor, small molecule
- 11,024 molecules share this mechanism.
- 11,071 completed, 2,807 terminated, 9,152 ongoing across sibling molecules.
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04851613CT.gov Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Laekna Limited · Start: February 18, 2022 · Completion: December 30, 2026 | P3 | Active Not Recruiting | — | — | — |
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Not yet implemented in v0.2 — scoring pending.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Afuresertib (this asset) | Laekna Limited | P3 | B · 60 |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | A |
| Camizestrant | AstraZeneca | P3 | BBB |
| Trastuzumab Emtansine | SWOG Cancer Research Network | P3 | BBB |
| Etoposide | Fudan University | P3 | BBB |
| Toripalimab | Zhejiang Cancer Hospital | P4 | BBB |
| Indocyanine Green | Isabelle Henskens | P3 | BBB |
| Everolimus | UNC Lineberger Comprehensive Cancer Center | P4 | BBB |
| Adriamycin | George Washington University | P4 | BBB |
+42 more in the Breast Cancer cohort
Other indications for Afuresertib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Cancer | — | P2 | BB · 69 |
| Cancer | — | P2 | BB · 64 |
| Neoplasm | — | P1/2 | BB · 64 |
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Not yet implemented in v0.2 — scoring pending.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Not yet implemented in v0.2 — scoring pending.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Not yet implemented in v0.2 — scoring pending.
Related assets
Citation
Floatz Terminal. Afuresertib in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 15, 2026. Accessed July 16, 2026. https://terminal.floatz.ai/assets/afuresertib-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →